Eliot Lurier
No más puestos en curso
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Robyn Hunter | F | 62 | 2 años | |
Rick Bodmer | M | - | 2 años | |
Robert Sexton | M | - | 2 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Michael Jebsen | M | 52 | 12 años | |
James M. Weaver | M | 58 | 10 años | |
Michael Loiacono | M | 58 | 7 años | |
Roger C. Colman | M | 70 | 5 años | |
Thomas E. Gardner | M | 76 |
NUCRYST Pharmaceuticals Corp.
NUCRYST Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activities is to develop, manufacture and commercialize innovative medical products that fight infection and inflammation. | 2 años |
John E. DeWolf | M | 68 |
Syracuse University
| 6 años |
Carol L. Amelio | F | 62 |
NUCRYST Pharmaceuticals Corp.
NUCRYST Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activities is to develop, manufacture and commercialize innovative medical products that fight infection and inflammation. | 4 años |
Dayton Misfeldt | M | 50 | 4 años | |
Goran Jurkovic | M | 53 | 2 años | |
Lionel Carnot | M | 56 | 4 años | |
Mehmet Ömer Arif Aras | M | - |
Syracuse University
| 5 años |
William C. Mills | M | 68 | 7 años | |
Illya Keith Maher | M | 56 | 2 años | |
Joseph M. Landstra | M | 46 | 3 años | |
Paul J. Schechter | M | 84 |
NUCRYST Pharmaceuticals Corp.
NUCRYST Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activities is to develop, manufacture and commercialize innovative medical products that fight infection and inflammation. | 5 años |
Catherine R. Ehrenberger | F | 65 | 2 años | |
Darlene DeRemer | F | 68 |
Syracuse University
| 6 años |
Bob Cuculich | M | - |
Syracuse University
| 7 años |
Steven Boyd | M | 43 | 2 años | |
Thomas R. Curran | M | 65 | 10 años | |
Lewis Bender | M | 65 | 4 años | |
Mary Chowning | F | 62 | 5 años | |
Craig Bell | M | 66 |
Syracuse University
| 5 años |
Salih Metin Ecevit | M | 78 |
Syracuse University
| 1 años |
Eric A. Marks | M | - |
Syracuse University
| 4 años |
Azureen binti Sultan Azlan Shah | F | 67 |
Syracuse University
| 4 años |
Rick Labs | M | 68 |
Syracuse University
| 4 años |
Dan Shaffer | M | - |
Syracuse University
| 4 años |
Wayne Burmaster | M | - |
Syracuse University
| 4 años |
Stephen Wilklow | M | - |
Syracuse University
| 4 años |
Wayne Smith | M | 64 |
Syracuse University
| 4 años |
Agoestiar Zoebier | M | 84 |
Syracuse University
| 2 años |
Stewart D. Aaron | M | - |
Syracuse University
| 3 años |
Todd Peter Engelson | M | - |
Syracuse University
| 4 años |
Greg O'Hara | M | - |
Syracuse University
| 4 años |
Karl F. Birkenfeld | M | - |
Syracuse University
| 4 años |
Robert S. Spiess | M | - |
Syracuse University
| 4 años |
Ruth K Ross | F | - |
Syracuse University
| 4 años |
Adnan Hasan Eisa Al-Hindi | M | 86 |
Syracuse University
| 3 años |
Yinglin Mark Xu | M | - |
Bridge Pharmaceuticals, Inc.
Bridge Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory-compliant drug development services globally. Bridge is known for its extensive work in toxicology, including vaccines, and safety pharmacology. The company's AAALAC-accredited facility in China was among the first labs to perform GLP studies for clients worldwide. Bridge Laboratories gives drug development clients-biotech/pharmaceutical firms, government agencies and virtual companies with strong outsourcing needs-a CRO choice that can dramatically improve the speed and cost-effectiveness of their drug development research programs. | 4 años |
Barry Turkanis | M | 70 |
Syracuse University
| 4 años |
Bob Pochily | M | - |
Syracuse University
| 5 años |
Bruce Werber | M | 70 |
Syracuse University
| 4 años |
Abdul Azmin bin Abdul Halim | M | 70 |
Syracuse University
| 4 años |
Richard Alexander | M | - |
Syracuse University
| 3 años |
Tre Mischka | M | - |
Syracuse University
| 3 años |
David Feldman | M | - |
Syracuse University
| 4 años |
John Romanow | M | - |
Syracuse University
| 4 años |
Daniel J. Pastuf | M | - |
Syracuse University
| 4 años |
Paul Brockway Boardman | M | - |
Syracuse University
| 5 años |
Terry Pigott | M | 67 |
Syracuse University
| 4 años |
Harris Scott Nydick | M | - |
Syracuse University
| 4 años |
Ronald Richard Redfield | M | 65 |
Syracuse University
| 3 años |
Karnaen Anwar Perwataatmadja | M | 84 |
Syracuse University
| 1 años |
Sharon Barner | F | 67 |
Syracuse University
| 4 años |
Doug Foulsham | M | - |
Syracuse University
| 4 años |
Katherine J. Turner | M | 70 |
NUCRYST Pharmaceuticals Corp.
NUCRYST Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activities is to develop, manufacture and commercialize innovative medical products that fight infection and inflammation. | 2 años |
Michael Terpin | M | 67 |
Syracuse University
| 3 años |
Michael S. Perlis | M | 71 |
Syracuse University
| 4 años |
Robert Bruce Kaimowitz | M | - |
Syracuse University
| 5 años |
Thomas F. Sheehan | M | - |
Syracuse University
| 4 años |
Eva Fromm O'Brien | F | - |
Syracuse University
| 4 años |
Cheang Neng Ng | M | 62 |
Syracuse University
| 4 años |
Robert Becker | M | - |
Syracuse University
| 4 años |
David M. Walke | M | 69 |
Syracuse University
| 4 años |
Craig Scholl | M | - |
Syracuse University
| 4 años |
Marc J. Ostro | M | 74 |
Syracuse University
| 3 años |
Jeanette H. Quay | F | - |
Syracuse University
| 3 años |
Edward Pettinella | M | 72 |
Syracuse University
| 2 años |
Jeffrey Fisher | M | 68 |
Syracuse University
| 4 años |
John Esposito | M | - |
Syracuse University
| 4 años |
David John Martinelli | M | 64 |
Syracuse University
| 4 años |
Carl G. Kleidman | M | 65 |
Syracuse University
| 4 años |
B. Baldanza | M | 62 |
Syracuse University
| 4 años |
Glenn S. Armstrong | M | 73 | 3 años | |
Alex Matturri | M | 66 |
Syracuse University
| 3 años |
John R. Sanford | M | 60 |
Syracuse University
| 4 años |
Abdulraouf bin Waleed Al-Baitar | M | 65 |
Syracuse University
| 4 años |
Mark A. Samuel | M | - |
Syracuse University
| 4 años |
Andy Feinman | M | - |
Syracuse University
| 4 años |
Kenneth S. Berryman | M | - |
Syracuse University
| 4 años |
Ira Winkler | M | - |
Syracuse University
| 5 años |
R. Earnie Seibert | M | - |
Syracuse University
| 4 años |
Larry A. Connors | M | - |
Syracuse University
| 4 años |
Richard J. Caserta | M | - |
Syracuse University
| 4 años |
Andrew T. Berlin | M | 63 |
Syracuse University
| 4 años |
Michael Fell | M | - |
Syracuse University
| 2 años |
James Bertonis | M | - |
Syracuse University
| 4 años |
Carolyn C. Lindheim | F | - |
Syracuse University
| 4 años |
Barry Mills | M | 73 |
Syracuse University
| 3 años |
Mark Shay | M | - |
Syracuse University
| 4 años |
David C. McDowell | M | 68 |
NUCRYST Pharmaceuticals Corp.
NUCRYST Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activities is to develop, manufacture and commercialize innovative medical products that fight infection and inflammation. | 4 años |
Rick Ehrlich | M | - |
Syracuse University
| 4 años |
Michael Brown | M | - |
Syracuse University
| 3 años |
Tushara Dave | M | - |
Syracuse University
| 1 años |
Edward Gaj | M | 67 |
NUCRYST Pharmaceuticals Corp.
NUCRYST Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activities is to develop, manufacture and commercialize innovative medical products that fight infection and inflammation. | 3 años |
Robert Delman | M | - |
Syracuse University
| 4 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 100 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Eliot Lurier
- Red Personal